Terms: = Head and neck cancer AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132
89 results:
1. cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2.
Liu F; Tang L; Liu H; Chen Y; Xiao T; Gu W; Yang H; Wang H; Chen P
Cell Death Dis; 2024 Apr; 15(4):279. PubMed ID: 38637504
[TBL] [Abstract] [Full Text] [Related]
2. Differential squamous cell fates elicited by NRF2 gain of function versus keap1 loss of function.
Takahashi J; Suzuki T; Sato M; Nitta S; Yaguchi N; Muta T; Tsuchida K; Suda H; Morita M; Hamada S; Masamune A; Takahashi S; Kamei T; Yamamoto M
Cell Rep; 2024 Apr; 43(4):114104. PubMed ID: 38602872
[TBL] [Abstract] [Full Text] [Related]
3. m6A/HOXA10-AS/ITGA6 axis aggravates oxidative resistance and malignant progression of laryngeal squamous cell carcinoma through regulating Notch and keap1/Nrf2 pathways.
Zhao K; Chen L; Xie Y; Ren N; Li J; Zhai X; Zheng S; Liu K; Wang C; Qiu Q; Peng X; Wang W; Liu J; Che Q; Fan J; Hu H; Liu M
Cancer Lett; 2024 Apr; 587():216735. PubMed ID: 38369001
[TBL] [Abstract] [Full Text] [Related]
4. ARID1A loss is associated with increased NRF2 signaling in human head and neck squamous cell carcinomas.
Nguyen V; Schrank TP; Major MB; Weissman BE
PLoS One; 2024; 19(2):e0297741. PubMed ID: 38358974
[TBL] [Abstract] [Full Text] [Related]
5. RASSF1A promotes radiosensitivity in nasopharyngeal carcinoma by promoting FoxO3a and inhibiting the Nrf2/TXNRD1 signaling pathway.
Si Y; Meng L; Zhang B; Wu Y; Du Q; Xu J; Qi J
Neoplasma; 2023 Oct; 70(5):633-644. PubMed ID: 38053374
[TBL] [Abstract] [Full Text] [Related]
6. Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia.
Paiboonrungruang C; Xiong Z; Lamson D; Li Y; Bowman B; Chembo J; Huang C; Li J; Livingston EW; Frank JE; Chen V; Li Y; Weissman B; Yuan H; Williams KP; Ben Major M; Chen X
Redox Biol; 2023 Nov; 67():102901. PubMed ID: 37776708
[TBL] [Abstract] [Full Text] [Related]
7. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.
Vokes NI; Galan Cobo A; Fernandez-Chas M; Molkentine D; Treviño S; Druker V; Qian Y; Patel S; Schmidt S; Hong L; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Negrao MV; Gibbons DL; Vaporciyan A; Le X; Wu J; Zhang J; Rigney U; Iyer S; Dean E; Heymach JV
Clin Cancer Res; 2023 Dec; 29(23):4958-4972. PubMed ID: 37733794
[TBL] [Abstract] [Full Text] [Related]
8. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract] [Full Text] [Related]
9. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via keap1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract] [Full Text] [Related]
10. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
[TBL] [Abstract] [Full Text] [Related]
11. Phosphorylation of phase-separated p62 bodies by ULK1 activates a redox-independent stress response.
Ikeda R; Noshiro D; Morishita H; Takada S; Kageyama S; Fujioka Y; Funakoshi T; Komatsu-Hirota S; Arai R; Ryzhii E; Abe M; Koga T; Motohashi H; Nakao M; Sakimura K; Horii A; Waguri S; Ichimura Y; Noda NN; Komatsu M
EMBO J; 2023 Jul; 42(14):e113349. PubMed ID: 37306101
[TBL] [Abstract] [Full Text] [Related]
12. Targeting Nrf2 for ferroptosis-based therapy: Implications for overcoming ferroptosis evasion and therapy resistance in cancer.
Lee J; Roh JL
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166788. PubMed ID: 37302427
[TBL] [Abstract] [Full Text] [Related]
13. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract] [Full Text] [Related]
14. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
15. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Negrao MV; Araujo HA; Lamberti G; Cooper AJ; Akhave NS; Zhou T; Delasos L; Hicks JK; Aldea M; Minuti G; Hines J; Aredo JV; Dennis MJ; Chakrabarti T; Scott SC; Bironzo P; Scheffler M; Christopoulos P; Stenzinger A; Riess JW; Kim SY; Goldberg SB; Li M; Wang Q; Qing Y; Ni Y; Do MT; Lee R; Ricciuti B; Alessi JV; Wang J; Resuli B; Landi L; Tseng SC; Nishino M; Digumarthy SR; Rinsurongkawong W; Rinsurongkawong V; Vaporciyan AA; Blumenschein GR; Zhang J; Owen DH; Blakely CM; Mountzios G; Shu CA; Bestvina CM; Garassino MC; Marrone KA; Gray JE; Patel SP; Cummings AL; Wakelee HA; Wolf J; Scagliotti GV; Cappuzzo F; Barlesi F; Patil PD; Drusbosky L; Gibbons DL; Meric-Bernstam F; Lee JJ; Heymach JV; Hong DS; Heist RS; Awad MM; Skoulidis F
Cancer Discov; 2023 Jul; 13(7):1556-1571. PubMed ID: 37068173
[TBL] [Abstract] [Full Text] [Related]
16. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state.
Yu W; Chen Y; Putluri N; Osman A; Coarfa C; Putluri V; Kamal AHM; Asmussen JK; Katsonis P; Myers JN; Lai SY; Lu W; Stephan CC; Powell RT; Johnson FM; Skinner HD; Kazi J; Ahmed KM; Hu L; Threet A; Meyer MD; Bankson JA; Wang T; Davis J; Parker KR; Harris MA; Baek ML; Echeverria GV; Qi X; Wang J; Frederick AI; Walsh AJ; Lichtarge O; Frederick MJ; Sandulache VC
Br J Cancer; 2023 Jun; 128(11):2013-2024. PubMed ID: 37012319
[TBL] [Abstract] [Full Text] [Related]
17. PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogramming.
Ma Y; Zhang X; Han X; Hao Z; Ji R; Li J; Guo W; Zhang Y; Guan F; Ma S
Mol Carcinog; 2023 Jun; 62(6):866-881. PubMed ID: 36988347
[TBL] [Abstract] [Full Text] [Related]
18. A pan-cancer analysis shows immunoevasive characteristics in NRF2 hyperactive squamous malignancies.
Härkönen J; Pölönen P; Deen AJ; Selvarajan I; Teppo HR; Dimova EY; Kietzmann T; Ahtiainen M; Väyrynen JP; Väyrynen SA; Elomaa H; Tynkkynen N; Eklund T; Kuopio T; Talvitie EM; Taimen P; Kallajoki M; Kaikkonen MU; Heinäniemi M; Levonen AL
Redox Biol; 2023 May; 61():102644. PubMed ID: 36867945
[TBL] [Abstract] [Full Text] [Related]
19. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in head and neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract] [Full Text] [Related]
20. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
[TBL] [Abstract] [Full Text] [Related]
[Next]
